DelveInsight’s, “Treatment Resistant Depression Pipeline Insight 2023” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Treatment Resistant Depression pipeline landscape. It covers the Treatment Resistant Depression pipeline drug profiles, including Treatment Resistant Depression clinical trials and nonclinical stage products. It also covers the Treatment Resistant Depression pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Treatment Resistant Depression Pipeline Report

 

DelveInsight’s Treatment Resistant Depression pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for Treatment Resistant Depression treatment.

 

The leading Treatment Resistant Depression Companies include Axsome Therapeutics, COMPASS Pathways, Merck Sharp & Dohme Corp., Navitor Pharmaceuticals, Inc., Taisho Pharmaceutical Co., Ltd.,  GH Research Limited, Novartis Pharmaceuticals, Reckitt Benckiser LLC, Relmada Therapeutics, Inc., SAGE Therapeutics, Navitor Pharmaceuticals, Sumitomo Dainippon Pharma, Alkermes, AbbVie, Janssen Pharmaceuticals, Celon Pharma, ACADIA Pharmaceuticals, Pherin Pharmaceuticals, ATAI Life Sciences, and others

 

Promising Treatment Resistant Depression Pipeline Therapies include AXS-05, ALKS-5461, Cariprazine, Seltorexant, Pimavanserin, MIJ821, Esketamine DPI, Psilocybin, REL-1017, and others

 

The Treatment Resistant Depression companies and academics are working to assess challenges and seek opportunities that could influence Treatment Resistant Depression R&D. The Treatment Resistant Depression therapies under development are focused on novel approaches to treat/improve Treatment Resistant Depression.

 

Request a sample and discover the recent breakthroughs happening in the Treatment Resistant Depression Pipeline landscape @ Treatment Resistant Depression Pipeline Outlook Report

 

Treatment Resistant Depression Overview

 

The term “treatment resistant depression” often refers to major depressive episodes that do not respond satisfactorily to at least two trials of antidepressant monotherapy; however, the definition has not been standardized. Pharmacologic treatment options comprise switching, combination, and potentiation strategy among the commonly used antidepressant drugs.

 

Recent Developmental Activities in the Treatment Resistant Depression Treatment Landscape

 

In February 2023, COMPASS Pathways initiated a Phase III, multicenter, randomized, double-blind, controlled study to investigate the efficacy, safety, and tolerability of two administrations of COMP360 in participants with Treatment-resistant Depression. The primary endpoint is to evaluate COMP360 25 mg versusCOMP360 1 mg for the change from baseline in MADRS total score. The secondary endpoints are to evaluateCOMP360 25 mg versus COMP360 1 mg for the change from baseline in Sheehan Disability Scale (SDS) total score, MADRS total score, and others. The trial is currently recruiting participants and is expected to be completed by March 2025, with an estimated enrolment of 568 participants.

 

In January 2023, COMPASS Pathways initiated a Phase III, multicenter, randomized, double-blind, placebo-controlled study to investigate the efficacy, safety, and tolerability of a single administration of COMP360in participants with Treatment-resistant Depression. The primary endpoint is to evaluate COMP360 25 mg versus placebo for the change from baseline in MADRS total score. The secondary endpoint is to evaluate COMP360 25mg versus placebo for the change from baseline in SDS total score. The trial is currently recruiting participants and is expected to be completed by October 2024, with an estimated enrolment of 378 participants.

 

In January 2020, the US Patent and Trademark Office granted the patent to COMPASS Pathways, US Patent No10,519,175, relating to methods of treating drug-resistant depression with a psilocybin formulation. The patent covers theuse of COMPASS’s synthesized investigational psilocybin formulation, COMP360, in a psilocybin therapy protocol forpatients with Treatment-Resistant Depression.

 

In March 2019, COMPASS Pathways initiated a Phase II, randomized study to evaluate the safetyand efficacy of Psilocybin in participants with treatment resistant depression. The trial enrolled 233 participantsand was completed in July 2021.

 

In October 2018, COMP360 received Breakthrough Therapy Designation from the US Food and Drug Administration forTreatment-resistant depression.

 

For further information, refer to the detailed Treatment Resistant Depression Drugs Launch, Treatment Resistant Depression Developmental Activities, and Treatment Resistant Depression News, click here for Treatment Resistant Depression Ongoing Clinical Trial Analysis

 

Treatment Resistant Depression Emerging Drugs Analysis

 

Psilocybin: COMPASS Pathways

Psilocybin therapy is an approach being investigated for the treatment of mental health challenges. It combines the pharmacological effects of psilocybin, a psychoactive substance, with psychological support. Psilocybin is an active ingredient in some species of mushrooms, often referred to as ‘magic mushrooms’. The company has developed a synthesised formulation of psilocybin, COMP 360, and is investigating the effectiveness of psilocybin therapy, initially in treatment-resistant depression.

 

AXS-05: Axsome Therapeutics

AXS-05 is a novel, oral, investigational NMDA receptor antagonist with multimodal activity being developed for the treatment of central nervous system (CNS) conditions. AXS-05 consists of a proprietary formulation and dose of dextromethorphan (DM) and bupropion. The dextromethorphan component of AXS-05 is an antagonist of the NMDA receptor, an ionotropic glutamate receptor, and a sigma-1 receptor agonist. These actions modulate glutamatergic neurotransmission. The bupropion component of AXS-05 serves primarily to increase the bioavailability of dextromethorphan, and is a norepinephrine and dopamine reuptake inhibitor

 

Treatment Resistant Depression Pipeline Therapeutics Assessment

There are approx. 25+ key companies which are developing the therapies for Treatment Resistant Depression. The companies which have their Treatment Resistant Depression drug candidates in the most advanced stage, i.e. preregistration include, Axsome Therapeutics.

 

Find out more about the Treatment Resistant Depression Pipeline Segmentation, Therapeutics Assessment, and Treatment Resistant Depression Emerging Drugs @ Treatment Resistant Depression Treatment Landscape

 

Scope of the Treatment Resistant Depression Pipeline Report

 

Coverage- Global

 

Treatment Resistant Depression Companies- Axsome Therapeutics, COMPASS Pathways, Merck Sharp & Dohme Corp., Navitor Pharmaceuticals, Inc., Taisho Pharmaceutical Co., Ltd.,  GH Research Limited, Novartis Pharmaceuticals, Reckitt Benckiser LLC, Relmada Therapeutics, Inc., SAGE Therapeutics, Navitor Pharmaceuticals, Sumitomo Dainippon Pharma, Alkermes, AbbVie, Janssen Pharmaceuticals, Celon Pharma, ACADIA Pharmaceuticals, Pherin Pharmaceuticals, ATAI Life Sciences, and others

 

Treatment Resistant Depression Pipeline Therapies include AXS-05, ALKS-5461, Cariprazine, Seltorexant, Pimavanserin, MIJ821, Esketamine DPI, Psilocybin, REL-1017, and others.

 

Treatment Resistant Depression Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

 

Dive deep into rich insights for drugs for Treatment Resistant Depression Pipeline Companies and Therapies, click here @ Treatment Resistant Depression Unmet Needs and Analyst Views

 

Table of Content

Introduction
Executive Summary
Treatment Resistant Depression: Overview
Pipeline Therapeutics
Therapeutic Assessment
Late Stage Products (Preregistration)
AXS-05: Axsome Therapeutics
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Psilocybin: COMPASS Pathways
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
SEP-378614: Sumitomo Dainippon Pharma
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Treatment Resistant Depression Key Companies
Treatment Resistant Depression Key Products
Treatment Resistant Depression- Unmet Needs
Treatment Resistant Depression- Market Drivers and Barriers
Treatment Resistant Depression- Future Perspectives and Conclusion
Treatment Resistant Depression Analyst Views
Treatment Resistant Depression Key Companies
Appendix

 

Got Queries? Find out the related information on Treatment Resistant Depression Mergers and acquisitions, Treatment Resistant Depression Licensing Activities @ Treatment Resistant Depression Recent Trends, and Future Perspectives

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/